Endocrine Abstracts

Background: Neuroendocrine neoplasms (NENs) are rare group of tumors with a different clinical course, prognosis and location. Radioligand therapy (RLT) is currently registered in gastroenteropancreatic (GEP) G1-G2 NENs. Tumors with an unknown point of origin, diagnosed outside the gastrointestinal tract and pancreas, or with Ki-67 >20%, do not qualify in many countries to standard RLT.Materials and Methods: 48 patients with progressive NENs of unkno...